ArticleBMC infectious diseases2025
Molecular epidemiology of extended-spectrum beta-lactamase producing Gram-negative bacteria among surgical site infection patients in Ethiopia: a multicenter prospective study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antimicrobial-Resistance Genetic Markers Among Multidrug-Resistant Enterobacteriaceae andFood science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extended-spectrum beta-lactamases (ESBLs) producing Gram-negative bacteria are public health threats. This study aims to characterize ESBL-producing Gram-negative bacteria (GNB) isolated from surgical site infection patients. A multicenter cross-sectional study was conducted at four hospitals located in central (Addis Ababa), southern (Hawassa), northern (Debre Tabor), and Southwestern (Jimma) parts of Ethiopia. A wound culture was performed among 752 surgical site infection (SSI) patients where 286 GNB were confirmed using MALDI-TOF; of which 135 were subjected to whole genome sequencing using the Illumina (HiSeq 2500) system. The overall genotypic frequencies of ESBL-producing GNB were 57.8%. The detection of ESBL-producing GNB at Hawassa, Debre Tabor, Jimma, and Addis Ababa was 21.5%, 19.3%, 29.6%, and 29.6%, respectively. The detection frequency of bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.